Cardiology News / Recent Literature Review / Second Quarter 2021

Cardiology News

Abstract

ESC Digital Congress 27-30/8/2021

TCT Meeting, San Francisco, 22-26/10/2021

42^nd Panhellenic Congress of Cardiology, Athens, 21-23/10/21

AHA Scientific Sessions 2021, Boston, MA, USA, 13-15/10/21

ACC.22, Washington, DC, USA, 2-4/4/22

EuroPCR, Paris, France, 17-20/5/22

Systemic Lupus Erythematosus (SLE) Patients Have a Higher Associated Risk of Heart Failure (HF) and Other Cardiovascular (CV) Outcomes Compared with Matched Control Subjects

Among 3,411 SLE patients (median age: 44.6 years; 86% women) who were matched with 13,644 controls, over a median of 8.5 years, absolute 10-year risks of outcomes were: HF, 3.71% vs 1.94%; atrial fibrillation, 4.35% vs 2.82%; ischemic stroke, 3.75% vs 1.92%; MI, 2.17% vs 1.49%; venous thromboembolism, 6.03% vs 1.68%; and the composite of ICD implantation/ventricular arrhythmias/cardiac arrest, 0.89% vs 0.30% (SLE patients, vs control subjects). SLE with subsequent HF was associated with higher mortality compared with HF without SLE (adjusted hazard ratio: 1.50) (Yafasova A et al, J Am Coll Cardiol 2021;77:1717-27).

Worse Long-Term Outcomes of Patients with Late Presentation of ST-Segment Elevation Myocardial Infarction (STEMI)

Of 13,707 patients (2011-2015), 5,826 consecutive patients diagnosed with STEMI within 48 h of symptom onset were categorized as late (12-48 h; n = 624) or early (<12 h; n = 5,202) presenters. Late presenters had worse clinical outcomes (180-day mortality: 10.7% vs. 6.8%; 3-year mortality: 16.2% vs. 10.6%; both log-rank p < 0.001), whereas presentation at ≥12 h of symptom onset was not independently associated with increased mortality after STEMI. The use of invasive interventional procedures decreased from the first (<12 h) to the second (12-24 h) 12-h interval of symptom-to-door time (“no primary PCI strategy” increased from 4.9% to 12.4%, and “no PCI” from 2.3% to 6.6%; both p < 0.001). Mortality rates increased from the first to the second 12-h interval of symptom-to-door time (from 6.8% to 11.2% for 180-day mortality; from 10.6% to 17.3% for 3-year mortality; all p < 0.05) (Cho KH et al, J Am Coll Cardiol 2021;77:1859-70).

High Dietary Sodium (HS) Intake Increases Plasma Volume, Lowers Standing Plasma Norepinephrine, and Decreases Δ Heart Rate in Patients With Postural Tachycardia Syndrome (POTS)

Among 14 POTS patients and 13 healthy control subjects (HC), age 23-49 years, enrolled in a crossover study with 6 days of low (LS) (10 mEq/d) or high sodium (HS) (300 mEq/d) diet, in POTS, the HS diet reduced upright heart rate and Δ heart rate compared with the LS diet. Total blood volume and plasma volume (PV) increased, and standing norepinephrine decreased with the HS compared with the LS diet. However, upright heart rate, Δ heart rate, and upright norepinephrine remained higher in POTS than in controls on the HS diet, despite no difference in the measured PV (Garland EM et al, J Am Coll Cardiol 2021; 77:2174-84)... (excerpt)